TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

PURPOSE: Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a hypoxia-activated prodrug selectively targeting hypoxic regions of solid tumors, delivers a cytotoxic warhead to the tumor, while maintaining...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Liu, Qian, Sun, Jessica D., Wang, Jingli, Ahluwalia, Dharmendra, Baker, Amanda F., Cranmer, Lee D., Ferraro, Damien, Wang, Yan, Duan, Jian-Xin, Ammons, W. Steve, Curd, John G., Matteucci, Mark D., Hart, Charles P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3985381/
https://ncbi.nlm.nih.gov/pubmed/22382881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1852-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados